UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 6.122

Sortiert nach

Guideline for the diagnosis and management of the rare coagulation disorders A United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology

British journal of haematology, 2014-11, Vol.167 (3), p.304-326

2014

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2023-04, Vol.329 (16), p.1367

2023

Link zum Volltext

Verfügbarkeit prüfen

First-line Therapy with Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with Decreased Allogeneic Blood Transfusion in Cardiovascular Surgery: A Retrospective, Single-center Cohort Study

Anesthesiology (Philadelphia), 2011-12, Vol.115 (6), p.1179-1191

2011

Link zum Volltext

Verfügbarkeit prüfen

Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

Journal of thrombosis and haemostasis, 2014-09, Vol.12 (9), p.1428-1436

2014

Link zum Volltext

Verfügbarkeit prüfen

Revisiting the Protein C Pathway: An Opportunity for Adjunctive Intervention in COVID-19?

Anesthesia and analgesia, 2020-09, Vol.131 (3), p.690-693

2020

Link zum Volltext

Verfügbarkeit prüfen

Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates

Thrombosis and haemostasis, 2013, Vol.110 (1), p.162

2013

Link zum Volltext

Verfügbarkeit prüfen

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers

Journal of thrombosis and haemostasis, 2018-01, Vol.16 (1), p.54-64

2018

Link zum Volltext

Verfügbarkeit prüfen

In vivo increase in thrombin generation by four‐factor prothrombin complex concentrate in apixaban‐treated healthy volunteers

Journal of thrombosis and haemostasis, 2015-10, Vol.13 (10), p.1799-1805

2015

Link zum Volltext

Verfügbarkeit prüfen

Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study

Journal of thrombosis and haemostasis, 2017-11, Vol.15 (11), p.2125-2137

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study

Journal of thrombosis and thrombolysis, 2019-08, Vol.48 (2), p.250-255

2019

Link zum Volltext

Verfügbarkeit prüfen

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Blood, 2024-05, Vol.143 (22), p.2256

2024

Link zum Volltext

Verfügbarkeit prüfen

Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry

British journal of haematology, 2019-03, Vol.184 (5), p.853-855

2019

Link zum Volltext

Verfügbarkeit prüfen

Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors

The New England journal of medicine, 2011-11, Vol.365 (18), p.1684-1692

2011

Link zum Volltext

Verfügbarkeit prüfen

Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review

American journal of health-system pharmacy, 2024-05, Vol.81 (11), p.e274-e282

2024

Link zum Volltext

Verfügbarkeit prüfen

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-01, Vol.20 (1), p.65-72

2014

Link zum Volltext

Verfügbarkeit prüfen

Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents

Thrombosis and haemostasis, 2012-02, Vol.107 (2), p.253

2012

Link zum Volltext

Verfügbarkeit prüfen

Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice

Journal of thrombosis and haemostasis, 2019-04, Vol.17 (4), p.567-573

2019

Link zum Volltext

Verfügbarkeit prüfen

Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury

Blood, 2011-08, Vol.118 (7), p.1943-1951

2011

Link zum Volltext

Verfügbarkeit prüfen

In vivo reversal of the anticoagulant effect of rivaroxaban with four‐factor prothrombin complex concentrate

British journal of haematology, 2016-01, Vol.172 (2), p.255-261

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding

British journal of haematology, 2019-03, Vol.184 (5), p.808-816

2019

Link zum Volltext

Verfügbarkeit prüfen

How I treat target-specific oral anticoagulant–associated bleeding

Blood, 2014-02, Vol.123 (8), p.1152-1158

2014

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of Urgent Warfarin Reversal With Frozen Plasma Versus Prothrombin Complex Concentrate in the Emergency Department

Circulation (New York, N.Y.), 2013-07, Vol.128 (4), p.360-364

2013

Link zum Volltext

Verfügbarkeit prüfen

Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2009-07, Vol.15 (4), p.904-910

2009

Link zum Volltext

Verfügbarkeit prüfen

Safety of coagulation factor concentrates guided by ROTEM™-analyses in liver transplantation: results from 372 procedures

BMC anesthesiology, 2019-06, Vol.19 (1), p.97-97, Article 97

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 6.122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(5.547)
Mit Volltextzugriff
(4.183)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Humans
(5.276)
Science & Technology
(4.888)
Life Sciences & Biomedicine
(4.800)
Male
(3.324)
Female
(2.970)
Biological And Medical Sciences
(2.726)
Medical Sciences
(2.627)
Middle Aged
(2.135)
Hematology
(1.944)
Adult
(1.926)
Time Factors
(1.895)
Cardiovascular System & Cardiology
(1.889)
Pharmacology. Drug Treatments
(1.740)
Aged
(1.663)
Blood Coagulation - Drug Effects
(1.596)
Blood. Blood Coagulation. Reticuloendothelial System
(1.560)
Anticoagulants - Administration & Dosage
(1.485)
Peripheral Vascular Disease
(1.460)
Risk Factors
(1.255)
Animals
(1.215)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

Guideline for the diagnosis and management of the rare coagulation disorders A United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology

Efficacy and Safety of Early Administration of 4-Factor Prothrombin Complex Concentrate in Patients With Trauma at Risk of Massive Transfusion: The PROCOAG Randomized Clinical Trial

First-line Therapy with Coagulation Factor Concentrates Combined with Point-of-Care Coagulation Testing Is Associated with Decreased Allogeneic Blood Transfusion in Cardiovascular Surgery: A Retrospective, Single-center Cohort Study

Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial

Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

Revisiting the Protein C Pathway: An Opportunity for Adjunctive Intervention in COVID-19?

Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers

In vivo increase in thrombin generation by four‐factor prothrombin complex concentrate in apixaban‐treated healthy volunteers

Reversal of apixaban anticoagulation by four‐factor prothrombin complex concentrates in healthy subjects: a randomized three‐period crossover study

Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study

Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial

Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry

Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors

Effect of low- versus high-dose 4-factor prothrombin complex concentrate in factor Xa inhibitor-associated bleeding: A qualitative systematic review

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors

Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents

Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice

Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury

In vivo reversal of the anticoagulant effect of rivaroxaban with four‐factor prothrombin complex concentrate

Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding

How I treat target-specific oral anticoagulant–associated bleeding

Outcomes of Urgent Warfarin Reversal With Frozen Plasma Versus Prothrombin Complex Concentrate in the Emergency Department

Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors

Safety of coagulation factor concentrates guided by ROTEM™-analyses in liver transplantation: results from 372 procedures

Suchergebnisse filtern